SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabets quarterly results and outlook sparked a sharp selloff as traders focused on slowing Search and advertising growth, heavy AI infrastructure spending, and pressure on free cash flow. The community is split between buyers calling the drop an overreaction and bears questioning whether AI can replace Searchs monetization and deliver returns on the spending, while bullish traders point to Cloud growth.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows post-earnings selloff reflects an earnings miss and softer guidance for contracted revenue growth, raising concerns that growth is slowing and AI demand may take longer to translate into results. Traders are divided between viewing the sharp drop as an overreaction and buying opportunity, and seeing it as a warning about valuation, future growth, and AI disruption risks.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets earnings-related selloff is driving attention, with traders focused on slowing Search growth and heavy AI infrastructure spending that has pressured cash flow, despite strong Google Cloud growth. The reaction is divided between bears worried about AIs impact on Search monetization and spending returns, and dip buyers who view the decline as an overreaction to solid Cloud momentum.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated lung-cancer trial results drove attention: the overall response rate was 24.6% across 69 patients, while a retrospective biomarker-selected subgroup showed a much higher 59.1% rate. Traders debated whether the subgroup supports a promising precision-treatment path or signals a narrower market and a less certain, potentially longer regulatory path; the mixed readout accompanied a steep selloff.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly earnings report is the focus, particularly AWS growth and whether heavy AI infrastructure spending will weigh on cash flow. After Alphabets sharp post-earnings drop, some traders fear a similar selloff, while others expect strong AWS results to support Amazon and the broader tech market.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is drawing attention amid a sharp selloff and intense focus on its Q3 earnings, with traders debating user growth, Googles AI-driven search changes, and the lack of clarity on AI data-licensing deals. Bears worry these factors could pressure Reddits advertising business, while bulls point to its growth and profitability and see the depressed price as an opportunity.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is drawing attention ahead of its quarterly earnings report, with traders split between hopes for a strong result and concerns that elevated expectations, margins, or guidance could trigger a sell-the-news reaction. The pre-report weakness is also being discussed alongside broader pressure on chip stocks after mixed Big Tech spending signals and Samsungs profit miss.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

A sharp selloff in silver after its earlier surge is dominating discussion, with many traders describing relentless selling and fearing further downside. Others see the decline as an oversold buying opportunity, while debate centers on macro pressure from rates, yields and the dollar versus unsubstantiated claims of market manipulation.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladocs Q3 results, particularly improving profitability and cash flow alongside a stronger EBITDA outlook, are driving the sharp rally. Bulls see signs of a turnaround and speculate that heavy short interest could amplify the move, while skeptics point to declining revenue and continued BetterHelp weakness.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is drawing attention as SK Hynixs strong results and outlook reinforced optimism about AI-driven memory demand and tight supply ahead of SanDisks own earnings report. Traders are anticipating a sector tailwind but debating whether high expectations could lead to a sell-the-news reaction and sharp volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact SueWallSt

BBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact SueWallSt BBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact SueWallStPR NewswireNEW...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNX INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and...

BBNX 5-DAY DEADLINE ALERT: Beta Bionics Investors with Losses Encouraged to Contact Hagens Berman, Securities Class Action Pending

BBNX 5-DAY DEADLINE ALERT: Beta Bionics Investors with Losses Encouraged to Contact Hagens Berman, Securities Class Action Pending BBNX 5-DAY DEADLINE ALERT: Beta Bionics Investors with Losses Encouraged to Contact Hagens Berman, Securities Class Action PendingPR NewswireSAN FRANCISCO, Oct. 29...

BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff Deadline

BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff Deadline BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff DeadlinePR...

BBNX Shareholder Alert: November 3, 2026 Lead Plaintiff Deadline in Beta Bionics, Inc. Securities Class Action - Contact Levi & Korsinsky

BBNX Shareholder Alert: November 3, 2026 Lead Plaintiff Deadline in Beta Bionics, Inc. Securities Class Action - Contact Levi & Korsinsky BBNX Shareholder Alert: November 3, 2026 Lead Plaintiff Deadline in Beta Bionics, Inc. Securities Class Action - Contact Levi & KorsinskyPR NewswireNEW YORK...

What's Next for Beta Bionics, Inc. Shareholders After 37% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

What's Next for Beta Bionics, Inc. Shareholders After 37% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline What's Next for Beta Bionics, Inc. Shareholders After 37% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud...

Beta Bionics (BBNX) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Beta Bionics Q3 2026 Earnings Call Transcript

Beta Bionics (NASDAQ:BBNX) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.read more...

Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates

Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +1.89% and +0.96%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

What Does Beta Bionics, Inc.'s 37% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline

What Does Beta Bionics, Inc.'s 37% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline What Does Beta Bionics, Inc.'s 37% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class...

$BBNX Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.52 down -57.58% YoY
• Reported revenue of $35.51M up 30.31% YoY
• Beta Bionics estimates FY2026 total revenue of approximately $124M to $126M, gross margin of 58.5% to 59.5%, and 37% to 39% of new patient starts reimbursed through PBP.

Stocktwits

Beta Bionics Inc.

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.52 down -57.58% YoY
• Reported revenue of $35.51M up 30.31% YoY
• Beta Bionics estimates FY2026 total revenue of approximately $124M to $126M, gross margin of 58.5% to 59.5%, and 37% to 39% of new patient starts reimbursed through PBP.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.52 down -57.58% YoY
• Reported revenue of $35.51M up 30.31% YoY
• Beta Bionics estimates FY2026 total revenue of approximately $124M to $126M, gross margin of 58.5% to 59.5%, and 37% to 39% of new patient starts reimbursed through PBP.

Beta Bionics reported larger operating losses, withdrew 3D Intelligences 510(k) application for additional simulator validation, and cited potential Q4 2026 revenue deferrals of up to $8.5M as prospective iLet users could await Mint.

Beta Bionics reported Q3 2026 net sales of $35.5M and PBP channel sales up 118%, received FDA clearance for Mint, completed type 2 pivotal-trial enrollment, and announced an Eversense integration agreement.

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral

Equity

Neutral Sentiment

Shares of Beta Bionics rose Thursday following the initiation of coverage by two Wall Street financial firms on the diabetes-focused medical technology company.Beta Bionics shares climbed 6.4% to close at $15.36 on Thursday, with an additional 0.8% gain in after-hours trading.Goldman Sachs assigned Beta Bionics a ‘Neutral’ rating with a $16 price target, as its technology targets a specific portion of the Type 1 diabetes market.&nbsp;Still, current consensus expectations already account for most of its immediate growth possibilities.&nbsp;According to analyst David Roman, Beta Bionics' current valuation reflects two key factors: its projected growth positions it to outperform diabetes peers and SMID-cap medtech firms in the near term.At the same time, the valuation also prices in the expected need for capital raises to reach cash flow breakeven.Meanwhile, Wolfe Research signaled optimism&nbsp;by initiating coverage with an ‘Outperform’ rating and a $20 price target.Beta Bionics created the iLet Bionic Pancreas device, which automates insulin delivery for individuals with Type 1 diabetes.Recently, the medical technology firm posted strong Q1 2025 results, with net sales growth of 36% year over year, bringing total sales to $17.6 million.&nbsp;The company saw growth through a 360% increase in Pharmacy Benefit Plan (PBP) channel sales and a 291% rise in the installed user base, reaching over 19,000.&nbsp;Operating losses rose to $18.6 million, resulting in a net loss of $28.7 million.Beta Bionics projects FY25 revenues between $82 and $87 million and gross margins between 50% and 53% while expecting a rise in new patient starts through the PBP channel.On Stocktwits, retail sentiment was ‘neutral’ amid ‘low’ message volume.Beta Bionics stock has declined 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, logos of Beta Bionics are displayed on mobile phone screen and computer screen in Ankara, Turkiye on September 5, 2023. (Photo by Arda Kucukkaya/Anadolu Agency via Getty Images)

Wolfe Research initiated coverage with an ‘Outperform’ rating and a $20 target, while Goldman Sachs started at ‘Neutral’ with a $16 target, citing balanced growth prospects and valuation.

$AMZN

$INTC

$RDDT

$SNDK

Which earnings release after the close will you be watching closest: $AMZN, $INTC, $RDDT, or $SNDK? 

Drop a comment for other tickers like $COIN, $SBUX, and $TWLO.

Coinbase Global Inc

Starbucks Corp

Twilio Inc

Which earnings release after the close will you be watching closest: 

? 

Drop a comment for other tickers like 

Stocktwits Polls

$BBNX longer time frames will look ugly, but I like the r/r here. Found on runner + 10% pullback scanu

Friend of Bill

$BBNX Hi Beta Bionics shareholders 

Any new details about the dual-hormone pump progress?

I believe that would be the day you make it big, as the only option offering both glucagon and insulin in one device in the entire industry. That would be a segment-redefining moment, transitioning from AID (Automated Insulin Delivery) to AGID (Automated Glucagon and Insulin Delivery). 

Glta 🖖

Alon Rosenzweig

$BBNX Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.52 down -57.58% YoY
• Reported revenue of $35.51M up 30.31% YoY
• Beta Bionics estimates FY2026 total revenue of approximately $124M to $126M, gross margin of 58.5% to 59.5%, and 37% to 39% of new patient starts reimbursed through PBP.

$BBNX reports earnings today after the close. I’m bullish heading into the report: BBNX has beaten EPS estimates in 6 of its last 8 reports, according to Stock Meadow. Analysts expect EPS of −$0.52. What are you watching for?

john

$BBNX Going to be one of the best new product stories of 2027 in MedTech…buy every dip here. Headed to $30+. 🔥🦾 $DXCM $PODD $IHI $XLV

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBNX Beta Bionics Inc.

Fundamentals

Latest BBNX News